Design and Invitro Evaluation of Olmesartan Medoxomil Floating Tablets
20 Pages Posted: 10 Feb 2020
Date Written: February 7, 2020
Abstract
The present study aimed to develop controlled release Floating Drug Delivery System (FDDS), which will remain in stomach for longer time while controlling drug release to achieve target release profile using a combination of Hydroxy Propyl Methyl Cellulose of different grades and Carbopol, Hydroxy Propyl Cellulose as Polymer. Olmesartan is an antihypertensive agent which belongs to the class angiotensin II receptor antagonists. Olmesartan medoxomil is a pro-drug that is converted to the active metabolite olmesartan in gastric region (Olmesartan medoxomil is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract). Olmesartan does not undergo further metabolism and does not interact with cytochrome P450 (CYP) enzymes. Hence we should perform the floating tablets of Olmesartan. The only adverse effect that occurred in >1% of patients treated with it. Therefore, reduction of side effects of olmesartan while prolonging its action by using controlled oral dosage forms is highly desirable. The floating tablets were evaluated for their hardness, friability, drug content, invitro buoyancy, invitro dissolution, swelling and stability studies.
Keywords: Olmesartan medoxomil, Hypertension, Floating tablet
Suggested Citation: Suggested Citation